Please assess the completion status of the following clinical trial:

Trial Title: Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Active, stable plaque psoriasis defined by the following criteria:~  * Body surface area (BSA) ≥ 10 % at screening and baseline~ * Or, PASI \>10 at screening and baseline~ * Or, PGA of Psoriasis status of moderate or worse (moderate, marked, or severe) at screening and baseline~ * Or, DLQI \> 10 at baseline~* Active fingernail psoriasis defined as target fingernail NAPSI ≥ 2 and overall NAPSI \> 14 - Target nail is defined as the nail with the highest nail score (matrix+bed scores) at baseline. Should more than one fingernail have the same score, the target fingernail will be chosen by the investigator.~* Failure of at least one systemic psoriasis therapy for nail psoriasis~* Eligible to receive biologic therapy for psoriasis in accordance to local guidelines~Exclusion Criteria:~* Evidence of Skin conditions other than psoriasis~* Psoralen plus ultraviolet radiation (PUVA), cyclosporine, alefacept, methotrexate, acitretin, or any other systemic anti-psoriasis therapy within 28 days of study drug initiation~* Prior exposure to any TNF-inhibitor. Prior exposure to efalizumab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): etanercept 50 mg SC injection twice weekly for 12 weeks reducing to etanercept 50 mg once weekly to week 24
- 2 (Type: ACTIVE_COMPARATOR): etanercept 50 mg SC once weekly for the complete 24 week treatment period

Based on this trial design, predict the completion outcome and termination type (if applicable).